Best Practice & Research Clinical Haematology
Volume 19, Issue 2 , Pages 301-310 , June 2006

Is there a role for consolidation therapy pre-transplantation?

  • Jacob M. Rowe, MD (Director)

      Affiliations

    • Corresponding Author InformationTel.: +972 4 854 2541; fax: +972 4 854 2343.

References 

  1. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461). Blood. 2002;100:4325–4336
  2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood. 1998;92:2322–2333
  3. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a southwest oncology group/ eastern cooperative oncology group study. Blood. 2000;96:4075–4083
  4. Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute myeloid leukemia. Hematology (American Society Hematology Education Program). 2001;62–86
  5. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK medical research council adult and children's leukaemia working parties. Lancet. 1998;351:700–708
  6. Cassileth PA, Harrington D, Appelbaum FR, et al. A comparison of chemotherapy versus autologous bone marrow transplantation versus allogeneic bone marrow. transplantation in first remission of adult acute myeloid leukemia: an intergroup study. E3489). N Engl J Med. 1998;339:1649–1656
  7. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European organization for research and treatment of cancer (EORTC) and the gruppo italiano malattie ematologiche maligne dell'adulto (GIMEMA) leukemia cooperative groups. N Engl J Med. 1995;332(4):217–223
  8. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The groupe ouest est leucemies aigues myeloblastiques (GOELAM). Blood. 1997;90:2978–2986
  9. Cahn JY, Labopin M, Sierra J, et al. No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute leukaemia working party of the European group for blood and marrow transplantation (EBMT). Br J Haematol. 2000;110:308–314
  10. Tallman MS, Rowlings PA, Milone G, et al. Effect of post remission chemotherapy prior to HLA-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood. 2000;96:1254–1258
  11. Stein AS, O'Donnell MR, Chai A, et al. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol. 1996;14:2206–2216
  12. Cassileth PA, Andersen J, Lazarus HM, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol. 1993;11:314–319
  13. Tallman MS, Perez WS, Lazarus HM, et al Pretransplant consolidation chemotherapy decreases leukemia relapse after autologous blood and marrow transplant for acute myelogenous leukemia in first remission. Biol Blood Marrow Transpl 2006, in press.
  14. Rowe JM. Uncertainties in the standard care of acute myelogenous leukemia. State-of-the-art mini-review. Leukemia. 2001;15:677–679

PII: S1521-6926(05)00121-0

doi: 10.1016/j.beha.2005.11.010

Best Practice & Research Clinical Haematology
Volume 19, Issue 2 , Pages 301-310 , June 2006

Article Tools

* Image Usage & Resolution